EGFR基因突变型非小细胞肺癌靶向治疗的预后疗效

Correlation between Prognosis and Efficacy of Targeted Therapy for EGFR Gene Expression in Non-small Cell Lung Cancer

目的探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)表皮生长因子受体(epidermal growth factor receptor,EGFR)基因表达靶向治疗的预后疗效。方法采用回顾性研究方法,选择EGFR突变型NSCLC患者92例作为研究对象,根据治疗方法的不同分为观察组与对照组,各46例。对照组给予常规PC方案化疗,观察组在对照组治疗的基础上给予厄洛替尼靶向治疗,2组都治疗观察2个周期,记录预后疗效。结果观察组的总有效率为89. 1%,显著高于对照组的69. 6%(P <0. 05)。观察组与对照组治疗后的Ig M与Ig A值都高于治疗前,观察组高于对照组(P <0. 05)。观察组治疗期间的不良反应主要为白细胞减少、血小板降低、消化道反应、肝肾损害等,多数为Ⅰ~Ⅱ级,均可耐受,对比差异无统计学意义(P> 0. 05)。随访至2018年8月,观察组的总生存时间与无瘤生存时间显著长于对照组(P <0. 05)。结论厄洛替尼靶向治疗EGFR基因突变型NSCLC能改善机体的免疫功能,提高治疗效果,延长患者的生存时间,且不会增加不良反应的发生。

Objective To investigate the prognostic effect of targeted therapy on non-small cell lung cancer( NSCLC) epidermal growth factor receptor( EGFR) gene expression. Methods Used retrospective study,172 patients with EGFR mutant NSCLC were selected and were divided into the 86 patients in the observation group and 86 patients in the control group,according to the different treatment methods. The control group were received conventional PC chemotherapy,and the observation group were received erlotinib targeted therapy on the basis of the control group. Both groups were treated for 2 cycles,and the prognosis were recorded. Results The total effective rate of the observation group were 89. 1%,which was significantly higher than that of the control group( 69. 6%)( P < 0. 05). The Ig M and Ig A values of the observation group and the control group were higher than those before treatment,and the observation group were higher than the control group( P < 0. 05). The toxic side effects during the treatment group were mainly leukopenia,thrombocytopenia,digestive tract reaction,liver and kidney damage,etc. Most of them were grade Ⅰ ~ Ⅱ,and were tolerated,the difference between the 2 groups were not statistically significant. Followed-up to August 2018,the total survival time and tumor-free survival time of the observation group were significantly longer than the control group( P < 0. 05). Conclusion The targeted treatment of EGFR gene mutant NSCLC with erlotinib can improve the immune function of the body,improve the therapeutic effect,prolong the survival time of patients,and increase the incidence of side effects.